Skip to main content
See every side of every news story
Published • loading... • Updated

Investigational Antibody-Drug Conjugate Shows Promise in Advanced Head and Neck Cancer

The antibody-drug conjugate also produced a 6.7-month median progression-free survival and an 81% estimated one-year survival in the phase I study.

Summary by News Medical
The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase 1 trial presented by researchers at The University of Texas MD Anderson Cancer Center.

4 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Newswise broke the news in Charlottesville, United States on Wednesday, November 18, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal